Skip to main content
Premium Trial:

Request an Annual Quote

Eli Lilly Canada Will Test MDS Proteomics Technology

NEW YORK, Jan. 14-Eli Lilly Canada will work with MDS Proteomics to evaluate PhosMap, an MDS technology that characterizes the changes in proteins that may develop during drug therapy.


Lilly will use the technology to assess the effects of kinase inhibitors on kinase targets. The collaboration is designed as a demonstration of the system.


Financial terms of the collaboration were not revealed. For further details, see the company website.


Eli Lilly Canada, headquartered in Toronto, is a division of Eli Lilly.


MDS Proteomics is a subsidiary of MDS.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.